Evidence map›Paper›PMID 35467778›Full record

ArticleCancer medicine2022

Germline mutations in penetrant cancer predisposition genes are rare in men with prostate cancer selecting active surveillance.

Lauren Brady, Lisa F Newcomb, Kehao Zhu, Yingye Zheng, Hilary Boyer, Navonil De Sarkar, Jesse K McKenney, James D Brooks, Peter R Carroll, Atreya Dash and 11 more

Open access · goldAbstract read
In one paragraph

Article in Cancer medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 13 institutions in 2 countries.

Lauren BradyDivision of Human Biology, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Lisa F NewcombDivision of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Kehao ZhuDivision of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Yingye ZhengDivision of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Hilary BoyerDivision of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Navonil De SarkarDivision of Human Biology, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Jesse K McKenneyRobert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, Ohio, USA.
James D BrooksDepartment of Urology, Stanford University, Stanford, California, USA.
Peter R CarrollDepartment of Urology, University of California, San Francisco, California, USA.
Atreya DashVA Puget Sound Health Care Systems, Seattle, WA, USA.
William J EllisDepartment of Urology, University of Washington, Seattle, Washington, USA.
Christopher P FilsonDepartment of Urology, Emory University School of Medicine, Atlanta, Georgia, USA.
Martin E GleaveDepartment of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
Michael A LissDepartment of Urology, University of Texas Health Sciences Center, San Antonio, Texas, USA.
Frances MartinDepartment of Urology, Eastern Virginia Medical School, Virginia Beach, Virginia, USA.
Todd M MorganDepartment of Urology, University of Michigan, Ann Arbor, Michigan, USA.
Ian M ThompsonCHRISTUS Medical Center Hospital, San Antonio, Texas, USA.
Andrew A WagnerDivision of Urology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Colin C PritchardDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.
Daniel W LinDivision of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Peter S NelsonDivision of Human Biology, Fred Hutchinson Cancer Center, Seattle, Washington, USA.ORCID 0000-0002-5451-5726
University of Washington · USFred Hutch Cancer Center · USBeth Israel Deaconess Medical Center · USChristus Health · USCleveland Clinic · USEastern Virginia Medical School · USEmory Healthcare · USStanford University · USThe University of Texas Health Science Center at San Antonio · USUniversity of British Columbia · CAUniversity of California, San Francisco · USUniversity of Michigan · USVA Puget Sound Health Care System · US

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4M
TRANSCRIPTOME AND PROTEOME STRATIFICATION OF PROSTATE ADENOCARCINOMA PHENOTYPESP50CA097186 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PETER S NELSON · 2002 to 2026
$58.1M
Prostate cancer Active Surveillance Study (PASS) Cohort: Infrastructure Support for Cancer ResearchU01CA224255 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI LIN, DANIEL W. · 2019 to 2023
$6.7M
NCI NIH HHS P30 CA015704NCI NIH HHS P50 CA097186NCI NIH HHS U01 CA224255
6 · The paper itself

Abstract

backgroundPathogenic germline mutations in several rare penetrant cancer predisposition genes are associated with an increased risk of aggressive prostate cancer (PC). Our objectives were to determine the prevalence of pathogenic germline mutations in men with low-risk PC on active surveillance, and assess whether pathogenic germline mutations associate with grade reclassification or adverse pathology, recurrence, or metastases, in men treated after initial surveillance.

methodsMen prospectively enrolled in the Canary Prostate Active Surveillance Study (PASS) were retrospectively sampled for the study. Germline DNA was sequenced utilizing a hereditary cancer gene panel. Mutations were classified according to the American College of Clinical Genetics and Genomics' guidelines. The association of pathogenic germline mutations with grade reclassification and adverse characteristics was evaluated by weighted Cox proportional hazards modeling and conditional logistic regression, respectively.

resultsOverall, 29 of 437 (6.6%) study participants harbored a pathogenic germline mutation of which 19 occurred in a gene involved in DNA repair (4.3%). Eight participants (1.8%) had pathogenic germline mutations in three genes associated with aggressive PC: ATM, BRCA1, and BRCA2. The presence of pathogenic germline mutations in DNA repair genes did not associate with adverse characteristics (univariate analysis HR = 0.87, 95% CI: 0.36-2.06, p = 0.7). The carrier rates of pathogenic germline mutations in ATM, BRCA1, and BRCA2did not differ in men with or without grade reclassification (1.9% vs. 1.8%).

conclusionThe frequency of pathogenic germline mutations in penetrant cancer predisposition genes is extremely low in men with PC undergoing active surveillance and pathogenic germline mutations had no apparent association with grade reclassification or adverse characteristics.

Indexed as

Germ-Line MutationProstatic NeoplasmsGenes, BRCA2Genetic Predisposition to DiseaseHumansMaleRetrospective StudiesWatchful Waitingactive surveillanceadverse pathologygermline mutationsprostate cancer

Identifiers

PMID35467778
PMCPMC9678104
OpenAlexW4224674578

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.